Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company: 14 sponsored US clinical trials, 13 recruiting.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company sponsors 14 registered US clinical trials on ClinicalTrials.gov, 13 of them currently recruiting. 2 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 2 trials.
Top-decile sponsor footprint
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
14 total, page 1 of 1
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
NCT07015242
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
NCT07115745
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
NCT07015983
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
NCT06788639
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
NCT06794268
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
NCT06788652
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
NCT06220201
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06297226
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06153251
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
NCT05869955
Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
NCT07603557
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 4 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Juno Therapeutics, Inc., a Bristol-Myers Squibb Company pipeline
13 recruiting of 14 indexed (93% open).
Phase mix: 2 late (III/IV) vs 9 early (I/II) (early-phase heavy).
Top condition: Multiple Myeloma (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company: open-pipeline peers nationwide
Peers matched on 14 registered trials and 93% open enrollment, not the therapeutic-area sidebar.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 14 trials (± recruiting share)
- 3-C Institute for Social Development · 14 trials · 0% recruiting
- Abbott Medical Optics · 14 trials · 0% recruiting
- Abbott RDx Cardiometabolic · 14 trials · 0% recruiting
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · 14 trials · 0% recruiting
Sponsors near 93% open enrollment (± trial volume)
- DualityBio · 90% recruiting · 10 trials
- Ottawa Heart Institute Research Corporation · 90% recruiting · 10 trials
- Efforia · 89% recruiting · 19 trials
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
Related
What to do with this Juno Therapeutics, Inc., a Bristol-Myers Squibb Company page
14 registered trials is a research-attention snapshot, not an endorsement of Juno Therapeutics, Inc., a Bristol-Myers Squibb Company or any single study.
- 13 of Juno Therapeutics, Inc., a Bristol-Myers Squibb Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Myeloma is the condition Juno Therapeutics, Inc., a Bristol-Myers Squibb Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company pipeline card: 14 registered trials from official public datasets.Report a data error.